Gain reproducible insight into protein behaviour in solution. Detect aggregation, optimise formulation stability and accelerate protein therapeutics development with Zetasizer.
Protein therapeutics - including recombinant proteins, enzymes, cytokines and growth factors - are among the most promising drug modalities in modern medicine. However, they are also among the most structurally sensitive and analytically challenging molecules to develop.
Small changes in molecular behaviour can lead to aggregation, instability or formulation failure, introducing risk into development programmes and slowing progress toward clinical success.
To move forward with confidence, scientists need analytical tools that provide clear, reproducible insight into protein behaviour in solution. That is why researchers worldwide rely on Zetasizer - delivering particle and molecular characterisation data they can trust.
With Zetasizer you can:
✔ Detect protein aggregation earlier
✔ Optimize formulation stability
✔ Understand protein interactions that drive instability
✔ Generate highly reproducible analytical data
Works with OmniTrust: Malvern Panalytical's compliance solution for the regulated environment
Even well-characterised protein therapeutics, including recombinant proteins, enzymes, cytokines and growth factors, can encounter failure in later stages of development due to:
These risks present a significant challenge in protein therapeutics development, particularly because they often originate at the molecular level, long before they can be identified using conventional analytical techniques.
Subtle changes in protein behaviour, such as shifts in surface charge, structural conformation or intermolecular interactions, can have a profound impact on stability, efficacy and manufacturability. These early instabilities are often missed during initial screening and only become apparent under real-world conditions such as scale-up, storage or transport.
Zetasizer is designed to uncover these hidden risks earlier in development.
Using highly sensitive dynamic light scattering (DLS), Zetasizer detects even the smallest changes in particle size, enabling scientists to identify early-stage aggregation before it becomes a critical issue. By providing clear, reproducible insight into protein behaviour in solution, Zetasizer supports faster, more informed decision-making and reduces the risk of costly late-stage failure.
Protein aggregation is one of the most common causes of instability in therapeutic protein development, where even small amounts of aggregation can reduce biological activity, increase immunogenicity risk and compromise regulatory approval.
The challenge is that aggregation often begins at the nanoscale, long before particles become visible or detectable by many traditional techniques. This is where the Zetasizer reveals early aggregation with exceptional sensitivity.
Using dynamic light scattering (DLS), Zetasizer measures subtle changes in particle size and detects the earliest stages of protein aggregation directly in solution. This enables scientists to identify aggregation risks earlier and make informed decisions about candidate selection and formulation strategy.
With Zetasizer, protein development teams can:
✔ Detect nanoscale aggregation before it becomes visible
✔ Monitor aggregation behaviour in native formulation conditions
✔ Screen protein candidates quickly to identify molecules with lower aggregation risk
The result is greater confidence in protein stability and fewer late-stage development surprises.
Protein therapeutics are highly sensitive to formulation conditions. Changes in pH, buffer composition, ionic strength or excipients can dramatically influence molecular interactions and trigger aggregation.
Developers must identify formulation conditions that maintain stability throughout manufacturing, storage and delivery, and this is where the Zetasizer provides powerful insight into protein stability.
By measuring both particle size and zeta potential, Zetasizer allows scientists to understand how proteins interact in solution and predict whether molecules will remain dispersed or begin to aggregate.
This enables rapid screening of formulation conditions and identification of buffers that promote long-term stability.
With Zetasizer, formulation scientists can:
✔ Predict colloidal stability using zeta potential measurements
✔ Compare multiple formulation conditions quickly and reliably
✔ Identify optimal buffer environments for stable protein formulations
This analytical insight allows teams to design more robust protein formulations earlier in development.
Protein therapeutics often exhibit complex molecular interactions, including self-association, oligomer formation and reversible clustering. These behaviours become particularly important in high-concentration formulations, where intermolecular interactions can lead to viscosity challenges or instability.
Understanding how proteins behave in solution is essential for developing therapeutic formulations that are both stable and manufacturable and Zetasizer reveals protein behaviour at the molecular level.
Dynamic light scattering provides insight into the hydrodynamic size and interaction behaviour of proteins, enabling scientists to detect self-association and intermolecular interactions before they become problematic.
By analysing proteins directly in solution, Zetasizer helps researchers better understand how molecules behave under real formulation conditions.
With Zetasizer, scientists can:
✔ Characterise molecular size and interaction behaviour in solution
✔ Detect early self-association and oligomer formation
✔ Support development of high-concentration therapeutic formulations
This deeper understanding enables teams to optimise protein formulations with confidence.
Automated workflows powered by the Sample Assistant bring greater consistency and control to protein therapeutics analysis. By standardising sample loading, measurement and data analysis, the system reduces operator variability and ensures that every protein sample is handled in exactly the same way. This is critical when working with structurally sensitive molecules, where even minor inconsistencies can obscure early signs of aggregation or instability.
For protein therapeutics such as recombinant proteins, enzymes and growth factors, detecting subtle changes in behaviour requires both sensitivity and reproducibility. The Sample Assistant supports this by delivering consistent measurement conditions across every run, allowing scientists to confidently compare protein candidates and formulation environments.
Designed for high-throughput studies, the system enables efficient screening of multiple protein samples and conditions without compromising analytical performance. Dynamic light scattering and zeta potential measurements retain their full sensitivity, while automated execution ensures reliable, reproducible datasets across larger studies.
By embedding consistency into every stage of analysis, automated workflows help protein development teams generate high-quality data they can trust. The result is clearer insight into protein behaviour, more efficient workflows and greater confidence when advancing candidates through development.
Zetasizer brings together sensitivity, reproducibility and ease of use to address the unique analytical challenges of protein therapeutics. From early discovery through to formulation development, it provides the insight needed to understand protein behaviour in solution and reduce risk throughout the development process.
With Zetasizer, you can:
✔ Detect early-stage protein aggregation with high-sensitivity dynamic light scattering (DLS)
✔ Measure zeta potential to understand surface charge and predict formulation stability
✔ Identify protein self-association and intermolecular interactions in solution
✔ Compare formulation conditions including pH, buffers and ionic strength with confidence
✔ Characterise protein behaviour at high concentrations to address viscosity challenges
✔ Generate highly reproducible data to support confident decision-making
✔ Enable high-throughput, standardised workflows with the Sample Assistant
✔ Screen protein candidates efficiently to identify molecules with improved stability profiles
✔ Reduce the risk of late-stage instability and reformulation
✔ Accelerate development timelines for protein therapeutics
By delivering reliable, reproducible insight into protein behaviour in solution, Zetasizer enables scientists to make better decisions earlier, supporting the development of stable, effective protein-based therapies with greater confidence.
Measure protein size and detect aggregation to optimise stability and support biologic drug development.
Characterise nanoparticle size and surface charge to optimise delivery efficiency and stability.
Verify particle size and stability to maintain product quality and regulatory compliance.
Analyse vesicle size and aggregation to support emerging therapeutic applications.
Characterize protein stability, aggregation and molecular behaviour to ensure efficacy and shelf life.
Analyse particle size and stability of antigens and delivery systems for effective vaccine performance.
Measure viral vector size and stability to ensure safe and effective gene delivery.
Understand nanoparticle size and surface properties to control drug release and targeting.
Measure size, zeta potential and concentration using DLS and NTA. Detect instability early and optimise biologics with Zetasizer and NanoSight.
The basics of Dynamic Light Scattering and electrophoretic light scattering will be discussed. I will review the Dynamic Light Scattering acronyms, i.e what is meant by NIBS and MADLS.
ZetaClass is a comprehensive webinar series on dynamic and electrophoretic light scattering where our experts walk you through the basic measuring principles, data interpretation, and tests performed to gauge data quality.
Join us as we unveil the new and expanded Zetasizer range: Zetasizer Advance. Dr Mike Kaszuba will introduce the new range and help you to pinpoint which system best fits your particle characterization requirements.
This webinar discusses some basic fundamentals of light scattering science and also common misconceptions about light scattering methods
In this webinar, you will learn about developing reliable and effective methods for dynamic light scattering (DLS) and electrophoretic light scattering (ELS) measurements using the Zetasizer Advance instrument. The presentation is geared toward users of DLS and ELS instruments who want to deepen their understanding of method development.
This webinar will explore how the Dynamic Light Scattering (DLS) technique, utilized by the Zetasizer Advance series, ensures compliance with United States Pharmacopeia (USP) guidelines, specifically USP 430.
This webinar will discuss each of the sections contained in United States Pharmacopeia (USP) 432 and what it means for users of Malvern Panalytical’s Zetasizer range of instruments who measure zeta potential in their workflow.
Join us to learn how to assess the quality of your data collected on the Zetasizer Advance instrument. Together we will go through real examples of data from particle size measurements that use Dynamic Light Scattering (DLS) and zeta potential measurements obtained with Electrophoretic Light Scattering (ELS) assessing data quality and sharing tips on how to improve confidence in the results.